HISTORY OF OUTCOME MEASURES FOR MYASTHENIA GRAVIS

被引：41

作者：

Burns, Ted M. ^{[1
]}

机构：

[1] Univ Virginia, Dept Neurol, Charlottesville, VA 22908 USA

来源：

MUSCLE & NERVE | 2010年 / 42卷 / 01期

关键词：

myasthenia gravis; outcome measures; MG Composite; MG-QOL15; rating scales; QUALITY-OF-LIFE; SELF-ADMINISTERED QUESTIONNAIRE; ALTERNATE-DAY PREDNISONE; LONG-TERM CORRELATION; MYCOPHENOLATE-MOFETIL; DOUBLE-BLIND; INTRAVENOUS IMMUNOGLOBULIN; ACETYLCHOLINE-RECEPTORS; RANDOMIZED-TRIAL; CLINICAL-TRIAL;

D O I：

10.1002/mus.21713

中图分类号：

R74 [神经病学与精神病学];

学科分类号：

摘要：

This review illustrates how measurements of clinical status in patients with myasthenia gravis have evolved from clinical descriptions and estimates of mortality rates to more sophisticated evaluative instruments, including numerical rating scales that measure strength, endurance, quality of life, and activities of daily living. The rationale and use of weighting and the importance of patient-reported outcomes are also discussed. The measurement of the steroid-sparing effect of an immunosuppressant is also reviewed. Muscle Nerve 42: 5-13, 2010

引用

页码：5 / 13

页数：9

共 94 条

[1] The MGTX experience: Challenges in planning and executing an international, multicenter clinical trial [J].

Aban, Inmaculada B. ;

Wolfe, Gil I. ;

Cutter, Gary R. ;

Kaminski, Henry J. ;

Jaretzki, Alfred, III ;

Minisman, Greg ;

Conwit, Robin ;

Newsom-Davis, John .

JOURNAL OF NEUROIMMUNOLOGY, 2008, 201 :80-84

[2] Standards of measurements in myasthenia gravis [J].

Barohn, RJ .

MYASTHENIA GRAVIS AND RELATED DISORDERS: BIOCHEMICAL BASIS FOR DISEASE OF THE NEUROMUSCULAR JUNCTION, 2003, 998 :432-439

[3] Reliability testing of the quantitative myasthenia gravis score [J].

Barohn, RJ ;

McIntire, D ;

Herbelin, L ;

Wolfe, GI ;

Nations, S ;

Bryan, WW .

MYASTHENIA GRAVIS AND RELATED DISEASES: DISORDERS OF THE NEUROMUSCULAR JUNCTION, 1998, 841 :769-772

[4]

BAROHN RJ, 2009, INT C MY GRAV PAR FR, P81

[5] Quantitative myasthenia gravis score: Assessment of responsiveness and longitudinal validity [J].

Bedlack, RS ;

Simel, DL ;

Bosworth, H ;

Samsa, G ;

Tucker-Lipscomb, B ;

Sanders, DB .

NEUROLOGY, 2005, 64 (11) :1968-1970

[6] PROGNOSIS OF MYASTHENIA-GRAVIS - A MULTICENTER FOLLOW-UP-STUDY OF 844 PATIENTS [J].

BEGHI, E ;

ANTOZZI, C ;

BATOCCHI, AP ;

CORNELIO, F ;

COSI, V ;

EVOLI, A ;

LOMBARDI, M ;

MANTEGAZZA, R ;

MONTICELLI, ML ;

PICCOLO, G ;

TONALI, P ;

TREVISAN, D ;

ZARRELLI, M .

JOURNAL OF THE NEUROLOGICAL SCIENCES, 1991, 106 (02) :213-220

[7] LONG-TERM CORRELATION OF CLINICAL COURSE AND ACETYLCHOLINE-RECEPTOR ANTIBODY IN PATIENTS WITH MYASTHENIA-GRAVIS [J].

BESINGER, UA ;

TOYKA, KV ;

HEININGER, K ;

FATEHMOGHADAM, A ;

SCHUMM, F ;

SANDEL, P ;

BIRNBERGER, KL .

ANNALS OF THE NEW YORK ACADEMY OF SCIENCES, 1981, 377 (DEC) :812-815

[8] MYASTHENIA-GRAVIS - LONG-TERM CORRELATION OF BINDING AND BUNGAROTOXIN BLOCKING ANTIBODIES AGAINST ACETYLCHOLINE-RECEPTORS WITH CHANGES IN DISEASE SEVERITY [J].

BESINGER, UA ;

TOYKA, KV ;

HOMBERG, M ;

HEININGER, K ;

HOHLFELD, R ;

FATEHMOGHADAM, A .

NEUROLOGY, 1983, 33 (10) :1316-1321

[9] Treatment of ocular symptoms in myasthenia gravis [J].

Bhanushali, Minal J. ;

Wuu, Joanne ;

Benatar, Michael .

NEUROLOGY, 2008, 71 (17) :1335-1341

[10] Myasthenia gravis and tumours of the thymic region - Report of a case in which the tumor was removed [J].

Blalock, A ;

Mason, MF ;

Morgan, HJ ;

Riven, SS .

ANNALS OF SURGERY, 1939, 110 :544-561

← 1 2 3 4 5 6 7 8 9 10 →